| Date | Title | Description |
| 04.11.2024 | The Impact of Boston’s Biotech Industry on Global Health | Share
Tweet
Share
Share
Email
The biotech industry in Boston is more than just a source of jobs or a pillar of the local economy; it is a powerful force in the global fight for better health. Known for its prestigious universities, research... |
| 22.08.2024 | Global Genes' Annual Week in RARE Event Heading to Kansas City | Global Genes
Global Genes is taking Week In RARE on the road to Kansas City, after having hosted this annual event in California for over 12 years. Moving the location annually will help make the event more accessible and equitable to the g... |
| 26.02.2023 | Blueprint Medicines Presents Registrational Data from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting | -- AYVAKIT achieved a statistically significant and clinically meaningful improvement in total symptom score that deepened over time, with improvements shown across all individual symptoms --
-- AYVAKIT achieved a statistically significant ... |
| 09.01.2023 | Healthcare Hires of Note | ProofPilot, a digital protocol automation platform for clinical trials, has added Bernadette Tosti to its executive leadership team in the role of chief product officer this week. Tosti has more than 15 years of experience in the digital cl... |
| 14.10.2022 | Taking Charge of a Cancer Diagnosis With Biomarker Testing | (BPT) - David was in his thirties and living a healthy life when doctors discovered a cancerous mass in his neck. He began treatment immediately, unsure about the journey ahead, and after enduring several therapies that left him feeling wor... |
| 02.08.2022 | Investing in IDRx | HIV ravaged entire communities before antiretroviral cocktail therapies helped turn the tide. Cocktail therapies combine multiple drugs: Some hit parts of the replication machinery the virus uses to make copies of itself, others block its a... |
| 10.06.2022 | Blueprint Medicines slips as it changes endpoint for trial in aim to greatly broaden Ayvakit label | Blueprint is forging ahead on its slow crawl to broaden its market for Ayvakit.
Having nabbed its fourth approval for the drug in 2021 for advanced systemic mastocytosis (SM) — a very rare disease in which a type of white blo... |
| 28.01.2022 | Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis | CAMBRIDGE, Mass., Jan. 28, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, r... |
| 29.11.2021 | Blueprint Medicines : to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics - Form 8-K | Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition
of Lengo Therapeutics
-- Adds LNG-451, a highly selective brain-penetrant precision therapy targeting EGFR exon 20 insertion mutations, to Blueprint ... |
| 28.10.2021 | Blueprint Medicines Reports Third Quarter 2021 Financial Results - Form 8-K | Blueprint Medicines Reports Third Quarter 2021 Financial Results
-- Strong AYVAKIT launch in advanced SM with $17.3 million in net product revenues in the first full quarter following U.S. approval --
-- Raising guidance for 2021 total reve... |
| 03.09.2021 | Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | |
| 04.08.2021 | Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | |
| 07.07.2021 | Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | |
| 04.06.2021 | Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | |
| 05.05.2021 | Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | |
| 11.04.2021 | Blueprint Medicines Data Highlight Clinical Leadership in Systemic Mastocytosis at AACR Annual Meeting 2021 | |
| 10.04.2021 | Blueprint Medicines Presents Preclinical Data Highlighting Broad Precision Therapy Research Pipeline at AACR Annual Meeting 2021 | |
| 07.04.2021 | Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | |
| 05.03.2021 | Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | |
| 03.03.2021 | Blueprint Medicines Announces EMA Validation of Type II Variation Marketing Authorization Application for AYVAKYT® (avapritinib) for the Treatment of Advanced Systemic Mastocytosis | |
| 05.02.2021 | Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | |
| 11.01.2021 | Blueprint Medicines Announces R&D Leadership Transitions | |
| 05.01.2021 | Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | |
| 04.12.2020 | Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | |
| 01.12.2020 | Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer | |
| 03.11.2020 | Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | |
| 25.09.2020 | Blueprint Medicines Announces European Commission Approval of AYVAKYT® (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors | |
| 23.09.2020 | Blueprint to take cancer drug back to FDA after positive results in rare blood disease | Shares of Blueprint (Nasdaq: BPMC) rose 9.7% on the Nasdaq when markets opened Tuesday, from $77.40 each to $84.93, and were up to $91.30 Wednesday morning. The company said it plans to apply for approval of the drug in advanced SM in the f... |
| 08.09.2020 | FDA green-lights second RET inhibitor, this time from Blueprint Medicines | Shares of Blueprint fell 3.7% on the Nasdaq when markets opened Tuesday and remained down 3.5% early in the afternoon.
“Targeted therapies have dramatically improved care for patients with non-small cell lung cancer driven by oncogenes, inc... |
| 14.07.2020 | Roche pays Blueprint $675M upfront for ex-U.S. development, commercialization rights to cancer drug | Under the terms of the deal, Roche will pay Blueprint $675 million upfront and make an equity investment of $100 million in the company. Blueprint is also eligible to receive milestone payments of up to $927 million, along with royalties on... |
| 31.05.2020 | Blueprint gets FDA priority review for competitor to newly approved Lilly cancer drug | Shares of Blueprint were down more than 4% on the Nasdaq following the news.
The company is presenting data on the drug in a poster at the American Society of Clinical Oncology’s annual meeting. The news follows the FDA’s accelerated approv... |
| 14.05.2020 | With new lung cancer data at ASCO, Blueprint Medicines nips at Eli Lilly’s heels | The ARROW abstract’s release closely follows the May 8 announcement that the Food and Drug Administration had given accelerated approval to Eli Lilly’s RET inhibitor, Retevmo (selpercatinib), in RET fusion-positive non-small cell lung cance... |
| 10.01.2020 | FDA approves Blueprint Medicines’ precision therapy for rare form of gastrointestinal cancer | Shares of Blueprint were up less than 1% on the Nasdaq when markets closed Thursday.
“Ayvakit is the first of what we hope will be many approved medicines enabled by our research platform,” Blueprint CEO Jeff Albers said in a statement. “No... |
| 08.01.2020 | Blueprint throws down targeted therapy gauntlet with new lung cancer data, FDA submission | Shares of the company were up about 1.8% on the Nasdaq following the news. The company also plans to submit for regulatory approval of the drug in medullary thyroid cancer in the second quarter of 2020.
Blueprint is one of multiple companie... |
| 28.10.2019 | FDA to split Blueprint’s cancer drug application in two | Shares of Blueprint were down about 5 percent on the NASDAQ Monday morning following the news. GIST is a sarcoma, meaning a cancer of the connective tissue. Avapritinib is an inhibitor of KIT and PDGFRa that is also in development for advan... |
| 30.07.2019 | The Big Decline In This Stock Is A Gift To Investors | Despite technological advances, most of medicine is still stubbornly one-size-fits-all. But last month, we got one step closer to personalized treatments. |
| 23.04.2017 | The March for Science: politics, puns, and plenty of numbers | Scientists are the kings and queens of data, accuracy, and facts. So in their honor, here are some figures and a recap of Saturday’s March for Science.
On Earth Day, April 22, 2017, hundreds of thousands of people (and quite a few dogs) too... |
| 12.01.2017 | Why that infamous LifeSci party might soon get women on boards | To his left is Kate Bingham, a managing partner at SV Life Sciences, who matches Rice’s enthusiasm and brings the necessary credibility. On the elevator on the way down, Bingham underscored Rice’s commitment. Like many others, she was skept... |
| 09.12.2016 | Synergy outlines upbeat PhIII data; Bluebird and Blueprint raising $375M | Synergy Pharmaceuticals $SGYP is following up on the late-stage success of its lead drug plecanatide for chronic idiopathic constipation with a new batch of upbeat Phase III data centered on irritable bowel syndrom... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 22.04.2016 | Why are there gnome statues decorating Blueprint Medicines? | Indeed, it’s a kinome-centric company: Developing kinase inhibitors – similar to the blockbuster cancer drug Gleevec, which many of Blueprint’s founders worked on before it was sold to Novartis.
Just about a year ago, Blueprint Medicines ra... |
| 03.12.2015 | Announcing the 2015 50 on Fire Winners | Tonight we unveiled the 2015 50 on Fire winners during our annual 50 on Fire celebration. These 50 winners represent a group of diverse individuals and organizations who are driving the innovation economy in Boston and beyond.
To select the... |
| 21.11.2014 | Personalized cancer drugmaker Blueprint Medicines rakes in $50M Series C | As with nearly all Third Rock-founded startups, Blueprint touts itself less as a biotech working on discrete therapeutics and more as a product engine, honing a system that can generate numerous potential therapies for years to come. That p... |
| 14.11.2014 | Blueprint Medicines Secures $50M in Series C |
CAMBRIDGE, MA, Leader in discovering and developing highly selective kinase inhibitors for genomically defined cancers, announced a $50 million Series C financing.
>> Click here for more funding data on Blueprint Medicines
>>... |
| 12.11.2014 | Blueprint Medicines Completes $50M Series C Financing | Blueprint Medicines, a Cambridge, MA-based developer of selective kinase inhibitors for genomically defined cancers, completed a $50m Series C financing.
The round was led by Partner Fund Management with participation from new investors Wel... |
| 08.01.2014 | Blueprint Medicines Completes $25M Series B Financing | Blueprint Medicines, a Cambridge, MA-based oncology company, completed a $25m Series B financing.
The round was led by Nextech Invest Ltd., with participation from founding investors Third Rock Ventures and Fidelity Biosciences as well as p... |
| 08.01.2014 | Blueprint Medicines Announces $25M Series B |
CAMBRIDGE, MA, Blueprint Medicines today announced the completion of a $25 million Series B financing.
>> Click here for more funding data on Blueprint Medicines
>> To export Blueprint Medicines funding data to PDF and Excel... |
| 08.10.2013 | Horizon Discovery and Blueprint Medicines enter oncology research service agreement | Horizon Discovery and Blueprint Medicines enter oncology research service agreement
08-10-2013
Horizon Discovery, a leading provider of research tools to support the development of personalized medicines, today announced it has signed a res... |
| 14.06.2012 | Venture firm launches rare blood disorder therapeutics developer with $41M | Among the company’s founders are three scientific researchers from University of California, San Francisco: Dr. Matthew Jacobson, Dr. Andrej Sali and Dr. Jack Taunton, and two Third Rock directors: Dr. Charles Homcy and Craig Muir. Dr. Mark... |
| 24.05.2012 | Blueprint Medicines Adds Fidelity Biosciences | Blueprint Medicines, a Cambridge, MA-based developer of personalized cancer therapies, announced Fidelity Biosciences as a new investor.
Fidelity Biosciences has joined existing founding investor Third Rock Ventures in the company’s previou... |
| 31.01.2012 | FDA-approved cancer drug gets revised label, better results with prolonged use | The cancer drug made the cover of Time magazine in 2001 around the time it was first approved by the FDA to treat patients with advanced Philadelphia chromosome positive chronic myeloid leukemia, a blood and bone marrow disease linked to a ... |
| 13.04.2011 | Google-ITA Acquisition Advances, Nano Terra Buys Surface Logix, Blueprint Medicines Gets $40M, & More Boston-Area Deals News | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
We saw acquisitions in the life sciences, Internet, and mobile sectors, as well as financings for startups spanning high-tech industries in New England.
—Akiban Technologies, ... |
| 11.04.2011 | Blueprint Medicines Closes $40M Series A Financing | Blueprint Medicines, a Boston, MA-based developer of personalized cancer therapies, closed a $40m Series A financing.
The round was led by Third Rock Ventures.
The company intends to use the funds to develop new cancer therapies.
Founded in... |
| - | Blueprint throws down targeted therapy gauntlet with new lung cancer data, FDA submission | A company developing targeted therapies for cancers expects to complete submission of data for one of its drugs in lung cancer by the end of the first quarter, based on top-line data from a trial of patients whose disease carries a particul... |
| - | Blueprint gets FDA priority review for competitor to newly approved Lilly cancer drug | Eli Lilly may have won the first-ever Food and Drug Administration approval for a drug that targets a genomic abnormality expressed in lung cancer, but another company has a potentially close competitor in the works.
Cambridge, Massachusett... |
| - | Personalized cancer drugmaker Blueprint Medicines rakes in $50M Series C | Blueprint Medicines recently announced a $50 million Series C round, meant to advance its two lead candidates through clinical trials in 2015 and fund the company’s proprietary kinase discovery platform and pipeline.
The round was led by Pa... |
| - | FDA approves Blueprint Medicines’ precision therapy for rare form of gastrointestinal cancer | The Food and Drug Administration has approved the first ever drug for a rare subset of a type of gastrointestinal tract cancer.
The agency on Thursday afternoon approved Blueprint Medicines’ Ayvakit (avapritinib) for unresectable or metasta... |
| - | Venture firm launches rare blood disorder therapeutics developer with $41M | Venture capital firm Third Rock Ventures has launched a drug development startup to treat genetic blood disorders, with sickle-cell anemia as its lead program target, providing $40.7 million in series A financing.
Global Blood Therapeutics‘... |
| - | With new lung cancer data at ASCO, Blueprint Medicines nips at Eli Lilly’s heels | A drug from Eli Lilly that targets rare mutations in lung and thyroid cancers has had Food and Drug Administration approval for less than a week, and a competitor is already on the way.
Cambridge, Massachusetts-based Blueprint Medicines ann... |
| - | FDA green-lights second RET inhibitor, this time from Blueprint Medicines | The Food and Drug Administration has approved the second drug that targets a certain genetic abnormality found in small percentages of patients with various solid tumors, but that represents a highly potent drug target.
Cambridge, Massachus... |
| - | FDA-approved cancer drug gets revised label, better results with prolonged use | The U.S. Food and Drug Administration has approved a revised label for cancer drug Gleevec following a clinical study that showed better results with prolonged use of the drug compared with the 12 months that has been recommended.
The U.S. ... |
| - | Why are there gnome statues decorating Blueprint Medicines? | Blueprint Medicines has captured the magic and whimsy of biotechnology: It’s got about a dozen or so one-foot high gnome statues in residence, or so reports Boston Business Journal:
On a tour of the headquarters, CEO Jeff Albers explained t... |
| - | Roche pays Blueprint $675M upfront for ex-U.S. development, commercialization rights to cancer drug | Swiss drugmaker Roche has signed an agreement potentially worth more than $1.7 billion focused on an investigational drug designed to treat cancers by targeting genetic drivers of disease.
The Basel, Switzerland-based drugmaker said Tuesday... |
| - | Why that infamous LifeSci party might soon get women on boards | It’s 7:15 a.m on the final day of the J.P. Morgan Healthcare Conference and Mike Rice, a founding partner of LifeSci Advisors, is exceedingly energetic.
It’s hard to hold that against him because it’s for a worthy cause. Rice is excited bec... |
| - | FDA to split Blueprint’s cancer drug application in two | The Food and Drug Administration will review a biotech company’s approval application for a cancer drug in two parts.
Cambridge, Massachusetts-based Blueprint Medicines said Monday that the FDA would split its application for the drug avapr... |
| - | The March for Science: politics, puns, and plenty of numbers | Scientists are the kings and queens of data, accuracy, and facts. So in their honor, here are some figures and a recap of Saturday’s March for Science.
On Earth Day, April 22, 2017, hundreds of thousands of people (and quite a few dogs) too... |
| - | Precision medicine: from targeted therapies to advancing outcomes in lung cancer | Over the past decade, precision medicine has garnered significant attention from the oncology community. By delivering therapies to patients most likely to benefit, precision medicine approaches have dramatically improved the outlook for pa... |
| - | Blueprint to take cancer drug back to FDA after positive results in rare blood disease | A drug already approved for a form of sarcoma that affects the digestive system has also shown efficacy in a rare type of blood cancer.
Cambridge, Massachusetts-based Blueprint Medicines said Tuesday that topline results of the Phase I EXPL... |
